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Clinical PerspectiveWhat Is New?We compared different anthropometric measurements of both traditional and a newly built index in a large Chinese population.We found that waist‐to‐height ratio outperformed body mass index, waist circumference, hip circumference, waist‐to‐hip ratio, and A Body Shape Index in predicting the presence of cardiovascular diseases and most cardiometabolic risk factors.The exception was that waist circumference was the best predictor of abnormal blood pressure.What Are the Clinical Implications?Waist‐to‐height ratio may be a more convenient and effective primary index to predict cardiovascular diseases and its risk factors.A growing body of evidence supports that avoidance of abdominal obesity is the prioritized primary prevention strategies for cardiovascular diseases, along with control of other major cardiometabolic risk factors.

Introduction {#jah34181-sec-0008}
============

Worldwide, obesity is one of the leading risk factors for cardiovascular diseases (CVDs) driven by the elevated level of cardiometabolic risk factors that are highly influenced by increased adiposity.[1](#jah34181-bib-0001){ref-type="ref"}, [2](#jah34181-bib-0002){ref-type="ref"}, [3](#jah34181-bib-0003){ref-type="ref"}, [4](#jah34181-bib-0004){ref-type="ref"}, [5](#jah34181-bib-0005){ref-type="ref"} In 2015, ≈107 million children and 603 million adults were obese, with a global prevalence of 5% and 12%, respectively. The World Health Organization (WHO) reported that obesity (ie, body mass index \[BMI\] ≥30 kg/m^2^) was linked to 4 million excess deaths worldwide and the loss of 120 million disability‐adjusted life‐years, equivalent to 7.1% of all causes of death and 4.9% of all adults' disability‐adjusted life‐years.[6](#jah34181-bib-0006){ref-type="ref"}, [7](#jah34181-bib-0007){ref-type="ref"} In China, the prevalence of overweight and obesity was 30.1% and 11.9%, respectively, in 2002, and increased to 32.0% and 67.6%, respectively, in 2012.[8](#jah34181-bib-0008){ref-type="ref"} In every 100,000 people, it was estimated that about 49 men and 34 women died from obesity.[7](#jah34181-bib-0007){ref-type="ref"}

BMI ≥30 kg/m^2^ is a widely used indictor for defining general obesity in a non‐Chinese population, and waist circumference (WC) \>90 cm for men (80 cm for women) is a cutoff measurement of abdominal obesity recommended by the WHO.[9](#jah34181-bib-0009){ref-type="ref"}, [10](#jah34181-bib-0010){ref-type="ref"} Many epidemiological studies investigated the predictive value of BMI for cardiometabolic risk factors and cardiovascular events and consistently showed that BMI had a lower discriminatory power than WC and waist‐to‐height ratio (WHtR) to distinguish individuals with high muscle mass from those with excess fat or abdominal obesity.[11](#jah34181-bib-0011){ref-type="ref"}, [12](#jah34181-bib-0012){ref-type="ref"}, [13](#jah34181-bib-0013){ref-type="ref"}, [14](#jah34181-bib-0014){ref-type="ref"}, [15](#jah34181-bib-0015){ref-type="ref"} Two systematic reviews indicated that WHtR was a better predictor for cardiometabolic risk factors and CVDs than BMI and WC,[16](#jah34181-bib-0016){ref-type="ref"}, [17](#jah34181-bib-0017){ref-type="ref"} but the results had significant heterogeneities as they identified more than 30 studies covering 15 ethnic populations.

A Body Shape Index (ABSI) is a new comprehensive adiposity index combining BMI and WC, which was developed by Krakauer in 2012, showing a better predictive value for mortality and CVDs than that of BMI or WC in whites.[18](#jah34181-bib-0018){ref-type="ref"}, [19](#jah34181-bib-0019){ref-type="ref"}, [20](#jah34181-bib-0020){ref-type="ref"}, [21](#jah34181-bib-0021){ref-type="ref"} ABSI has also been adopted by several small Asian studies (Indonesia, Iran, and China) to investigate the association with hypertension, mortality, and metabolic syndrome,[22](#jah34181-bib-0022){ref-type="ref"}, [23](#jah34181-bib-0023){ref-type="ref"}, [24](#jah34181-bib-0024){ref-type="ref"} but none of these previous studies examined the association with CVDs and there is a lack of knowledge on the predictive value of ABSI for cardiovascular risk factors among the Chinese population. In addition, there has been no research comparing the discriminatory power between ABSI and other anthropometric measurements for cardiometabolic risk factors and CVD risk in a single large Chinese population.

This study aimed to compare the predictive value of a newly developed ABSI in a large Chinese population with other 5 conventional obesity‐related anthropometric indices (BMI, WC, hip circumference \[HC\], waist‐to‐hip ratio \[WHR\], and WHtR) for predicting cardiometabolic risk factors and CVDs. The optimal thresholds of these anthropometric indices were also evaluated.

Methods {#jah34181-sec-0009}
=======

The data, analytic methods, and study materials will not be made available to other researchers for purposes of reproducing the results or replicating the procedure.

Enrollment of Participants {#jah34181-sec-0010}
--------------------------

Participants in this study were a subset of Chinese subjects who were enrolled from the baseline survey of the PURE (Prospective Urban and Rural Epidemiology) study during 2005--2009. PURE is a large prospective cohort of 153 996 individuals enrolled from 628 urban and rural communities in 17 low‐, middle‐, and high‐income countries including China.[25](#jah34181-bib-0025){ref-type="ref"}, [26](#jah34181-bib-0026){ref-type="ref"}, [27](#jah34181-bib-0027){ref-type="ref"}

Being a major partnership of PURE, PURE‐China recruited 46 285 subjects (aged 35--70 years) from 115 communities (70 urban and 45 rural) in 12 provinces in China, representing various levels of development and encompassing a large sociocultural diversity.[28](#jah34181-bib-0028){ref-type="ref"}, [29](#jah34181-bib-0029){ref-type="ref"} The PURE‐China cohort study was approved by an institutional review committee and all participants gave informed consent. For the current analyses, we excluded participants without anthropometric indices (n=715; 1.5%) or blood sample data (n=1522; 3.3%). Thus, 44 048 participants were included in this study.

Data Collection {#jah34181-sec-0011}
---------------

Trained research staff interviewed each participant using standardized questionnaires and collected information on demographic data, lifestyle behaviors (such as physical activity level and energy intake), and medical history.[30](#jah34181-bib-0030){ref-type="ref"} Physical activity was obtained using the International Physical Activity Questionnaire and evaluated in metabolic equivalents.[31](#jah34181-bib-0031){ref-type="ref"} Daily energy intake was assessed using a validated Food Frequency Questionnaire.[32](#jah34181-bib-0032){ref-type="ref"}, [33](#jah34181-bib-0033){ref-type="ref"}

Anthropometric Measurements {#jah34181-sec-0012}
---------------------------

Anthropometric measurements were collected by trained staff following standard procedures. Height was measured to the nearest 0.1 cm without shoes using a standard stadiometer. Weight was measured in subjects wearing light indoor clothing to the nearest 0.1 kg using a rigid measurement device. WC was measured to the nearest 0.1 cm at the midpoint between the lowest rib margin and the level of the anterior superior iliac crest by a flexible anthropometric tape. HC was measured to the nearest 0.1 cm at the greatest protrusion of the gluteal muscles. WHR and WHtR were calculated as WC/HC and WC/height, respectively. ABSI was calculated using the following formula: $\frac{\text{WC}}{\text{BMI}^{2/3}\text{Height}^{1/2}}$.[18](#jah34181-bib-0018){ref-type="ref"} Systolic blood pressure (SBP) and diastolic blood pressure (DBP) were measured 2 times after resting for 5 minutes in the sitting position using an OMRON blood pressure (BP) monitor. If there was a difference \>5 mm Hg, measurements were repeated.

Definitions of Outcomes {#jah34181-sec-0013}
-----------------------

Dyslipidemia, abnormal BP, and hyperglycemia were considered cardiometabolic risk factors. Dyslipidemia was defined by criteria of the 2016 Chinese guidelines for the management of dyslipidemia in adults.[34](#jah34181-bib-0034){ref-type="ref"} Dyslipidemia was defined if any of the following blood lipid measurements were abnormal: total cholesterol ≥5.2 mmol/L; low‐density lipoprotein cholesterol ≥3.4 mmol/L; high‐density lipoprotein cholesterol ≤1.0 mmol/L; or triglycerides ≥1.7 mmol/L. Abnormal BP was defined as self‐reported hypertension or SBP ≥120 mm Hg and/or DBP ≥80 mm Hg.[35](#jah34181-bib-0035){ref-type="ref"} Participants were regarded as being hyperglycemic if they had self‐reported diabetes or a recent laboratory result of fasting blood glucose level ≥5.6 mmol/L.[36](#jah34181-bib-0036){ref-type="ref"} Self‐reported physician‐diagnosed CVDs included coronary heart disease, heart failure, and other CVDs (arrhythmia, valvular heart disease, cardiomyopathy, and myocarditis).

Statistical Analyses {#jah34181-sec-0014}
--------------------

Continuous data were reported as means and SDs and categorical data as frequencies with proportions. Means and proportions were compared using 2‐sided *t* tests and χ^2^, respectively. Three different logistic regression models were used to evaluate standardized (per 1‐SD increase) associations of obesity‐related anthropometric indices with cardiometabolic risk factors and CVDs. Odds ratios (ORs) were standardized by using transformed observations \[(observation−mean)/SD\] in the models. Potential confounding factors to be adjusted in the multiple regression models were sociodemographic variables (age, sex, regions, location, and education levels), lifestyle characteristics (physical activity and daily energy intake), self‐reported disease history, and family history of chronic diseases. Missing adjusted factors were imputed by maximum frequency for statistical analysis. We also performed sensitivity analysis for original data (Tables [S1](#jah34181-sup-0001){ref-type="supplementary-material"} through S5) and found that the results remained consistent.

For each index, receiver operator characteristic (ROC) curve analysis was used to identify the value with the maximum sum of sensitivity and specificity as a predictor of cardiometabolic risk factors and CVDs. The optimal cut point for each measure of adiposity in detecting cardiometabolic risk factors was chosen as the point on the curve with the highest Youden Index (sensitivity+specificity−1). Furthermore, we performed 2 subgroup analyses based on sex and age group. All reported *P* values were 2‐sided and \<0.05 was considered significant. All analyses were performed in SAS version 9.4 (SAS Institute Inc).

Results {#jah34181-sec-0015}
=======

Demographic data of 44 048 eligible participants included in the current study are presented in Table [1](#jah34181-tbl-0001){ref-type="table"}. There was a statistically significant difference between participants with and without CVDs with respect to age, sex, living area, education, lifestyle characteristics, and family disease history. People with CVDs had significantly higher anthropometric indices (*P*\<0.001) and laboratory indicators than those without CVDs.

###### 

Participants Sociodemographic and Lifestyle Characteristics

  Characteristic[a](#jah34181-note-0004){ref-type="fn"}     Total Sample (N=44 048)   CVDs[b](#jah34181-note-0005){ref-type="fn"} (n=2755)   No CVDs (n=41 293)   *P* Value[c](#jah34181-note-0006){ref-type="fn"}
  --------------------------------------------------------- ------------------------- ------------------------------------------------------ -------------------- --------------------------------------------------
  Age                                                       51.2±9.8                  51.3±8.8                                               50.8±9.7             \<0.001
  Sex (Male)                                                18 139 (41.2)             954 (34.6)                                             17 185 (41.6)        \<0.001
  Education                                                                                                                                                       \<0.001
  Low (none, primary, or unknown)                           14 941 (34.0)             1129 (41.1)                                            13 812 (33.5)        
  Middle (secondary, high, higher secondary school)         25 142 (57.2)             1342 (48.9)                                            23 800 (57.8)        
  High (trade, college, or university)                      3857 (8.78)               276 (10.0)                                             3581 (8.7)           
  Regions                                                                                                                                                         \<0.001
  Eastern                                                   23 313 (52.9)             1372 (49.8)                                            21 941 (53.1)        
  Middle                                                    10 014 (22.7)             598 (21.7)                                             9416 (22.8)          
  Western                                                   10 721 (24.3)             785 (28.5)                                             9936 (24.1)          
  Current smoking[d](#jah34181-note-0007){ref-type="fn"}    9806 (22.5)               420 (15.4)                                             9386 (23.0)          \<0.001
  Current drinking[e](#jah34181-note-0008){ref-type="fn"}   9258 (21.1)               402 (14.7)                                             8856 (21.6)          \<0.001
  Physical activity (MET score level)                                                                                                                             0.0182
  Low (\<600 MET min/wk)                                    5354 (12.7)               290 (11.1)                                             5064 (12.8)          
  Middle (600--3000 MET min/wk)                             5354 (43.7)               1189 (45.5)                                            17 217 (43.6)        
  High (\>3000 MET min/wk)                                  5354 (43.5)               1132 (43.4)                                            17 197 (43.6)        
  SBP, mm Hg                                                133.5±22.4                140.3±23.4                                             133.1±22.3           \<0.001
  DBP, mm Hg                                                82.8±13.2                 85.3±12.6                                              82.6±13.3            \<0.001
  Glucose, mmol/L                                           5.6±1.6                   5.9±2.1                                                5.56±1.5             \<0.001
  Cholesterol, mmol/L                                       4.7±1.0                   4.9±1.1                                                4.67±1.0             \<0.001
  Triglyceride, mmol/L                                      1.6±1.2                   1.8±1.3                                                1.6±1.2              \<0.001
  HDL‐C, mmol/L                                             1.4±0.4                   1.4±0.5                                                1.4±0.3              \<0.001
  LDL‐C, mmol/L                                             2.6±0.8                   2.8±0.9                                                2.6±0.8              \<0.001
  Weight, kg                                                63.8±12.1                 65.4±12.7                                              63.7±12.1            \<0.001
  Height, m                                                 160.8±8.2                 159.8±8.3                                              160.9±8.3            \<0.001
  BMI, kg/m^2^                                              24.6±4.0                  25.6±4.3                                               24.6±4.0             \<0.001
  WC, cm                                                    81.1±10.5                 84.6±10.9                                              80.9±10.5            \<0.001
  HC, cm                                                    94.3±8.1                  96.7±8.5                                               94.1±8.0             \<0.001
  WHR                                                       0.86±0.07                 0.87±0.08                                              0.86±0.07            \<0.001
  WHtR                                                      0.50±0.06                 0.53±0.07                                              0.50±0.06            \<0.001
  ABSI, m^7/6^/kg^2/3^                                      0.08±0.01                 0.08±0.01                                              0.08±0.01            0.0657
  Dyslipidemia[f](#jah34181-note-0009){ref-type="fn"}       22 959 (52.12)            1785 (64.8)                                            21 174 (51.3)        \<0.001
  Abnormal BP[g](#jah34181-note-0010){ref-type="fn"}        33 278 (75.55)            2345 (85.1)                                            30 933 (74.9)        \<0.001
  Hyperglycemia[h](#jah34181-note-0011){ref-type="fn"}      16 977 (38.54)            1294 (47.0)                                            15 683 (38.0)        \<0.001

ABSI indicates A Body Shape Index; BMI, body mass index; HC, hip circumference; MET, metabolic equivalent; WC, waist circumference; WHR, waist‐to‐hip ratio; WHtR, waist‐to‐height ratio.

Data are presented as mean±SD or number (percentage). The missing values are as follows: education: 108; smoking status: 464; drinking status: 255; and physical activity level: 1959.

Coronary heart disease or heart failure or other cardiovascular diseases (CVDs; arrhythmia, valvular heart disease, cardiomyopathy, and myocarditis).

CVDs vs no CVDs.

Current smoking: consuming at least 1 tobacco product per day.

Current drinking: consuming alcohol at least once a month.

Dyslipidemia: total cholesterol ≥5.2 mmol/L or low‐density lipoprotein cholesterol (LDL‐C) ≥3.4 mmol/L or high‐density lipoprotein cholesterol (HDL‐C) ≤1.0 mmol/L or triglycerides ≥1.7 mmol/L.

Abnormal blood pressure (BP): self‐reported hypertension or systolic BP (SBP) ≥120 mm Hg and/or diastolic BP (DBP) ≥80 mm Hg.

Hyperglycemia: self‐reported diabetes or fasting blood glucose level ≥5.6 mmol/L.

The associations between anthropometric measurements and cardiometabolic risk factors and CVDs are illustrated in Table [2](#jah34181-tbl-0002){ref-type="table"}. Higher levels of adiposity were associated with greater risks of cardiometabolic risk factors and CVDs in both the univariable and multivariable models (*P*\<0.001). The standardized adjusted ORs for dyslipidemia, abnormal BP, hyperglycemia, and CVDs ranged from 1.284 to 1.674, from 1.150 to 1.879, from 1.064 to 1.343, and from 1.176 to 1.353, respectively. WHtR showed a higher OR than BMI, WC, HC, WHR, and ABSI for all cardiometabolic risk factors and CVDs.

###### 

Crude and Adjusted ORs (Per 1‐SD Increase) for Cardiometabolic Risk Factors and CVDs in Relation to Anthropometric Indices (N=44 048)

  Outcomes                                               Model 1 OR (95% CI)[a](#jah34181-note-0013){ref-type="fn"}   Model 2 OR (95% CI)[b](#jah34181-note-0014){ref-type="fn"}   Model 3 OR (95% CI)[c](#jah34181-note-0015){ref-type="fn"}
  ------------------------------------------------------ ------------------------------------------------------------ ------------------------------------------------------------ ------------------------------------------------------------
  Dyslipidemia[d](#jah34181-note-0016){ref-type="fn"}                                                                                                                              
  BMI                                                    1.556 (1.522--1.591)                                         1.528 (1.494--1.563)                                         1.524 (1.490--1.559)
  WC                                                     1.671 (1.637--1.705)                                         1.651 (1.616--1.687)                                         1.647 (1.612--1.683)
  HC                                                     1.454 (1.425--1.483)                                         1.434 (1.404--1.464)                                         1.431 (1.401--1.461)
  WHR                                                    1.513 (1.482--1.546)                                         1.551 (1.516--1.588)                                         1.547 (1.511--1.583)
  WHtR                                                   1.699 (1.665--1.735)                                         1.679 (1.643--1.716)                                         1.674 (1.638--1.711)
  ABSI                                                   1.333 (1.307--1.360)                                         1.285 (1.259--1.313)                                         1.284 (1.257--1.312)
  Abnormal BP[e](#jah34181-note-0017){ref-type="fn"}                                                                                                                               
  BMI                                                    1.842 (1.791--1.894)                                         1.738 (1.693--1.785)                                         1.734 (1.689--1.780)
  WC                                                     1.893 (1.846--1.940)                                         1.810 (1.762--1.860)                                         1.806 (1.758--1.855)
  HC                                                     1.523 (1.488--1.559)                                         1.553 (1.514--1.593)                                         1.547 (1.508--1.587)
  WHR                                                    1.721 (1.678--1.765)                                         1.552 (1.510--1.596)                                         1.551 (1.509--1.595)
  WHtR                                                   1.842 (1.797--1.888)                                         1.886 (1.832--1.943)                                         1.879 (1.824--1.935)
  ABSI                                                   1.340 (1.310--1.371)                                         1.150 (1.122--1.178)                                         1.150 (1.122--1.178)
  Hyperglycemia[f](#jah34181-note-0018){ref-type="fn"}                                                                                                                             
  BMI                                                    1.321 (1.293--1.348)                                         1.321 (1.293--1.350)                                         1.320 (1.292--1.348)
  WC                                                     1.356 (1.330--1.383)                                         1.335 (1.308--1.364)                                         1.333 (1.306--1.362)
  HC                                                     1.206 (1.183--1.230)                                         1.211 (1.186--1.237)                                         1.209 (1.184--1.235)
  WHR                                                    1.317 (1.290--1.344)                                         1.277 (1.250--1.306)                                         1.276 (1.248--1.304)
  WHtR                                                   1.384 (1.357--1.412)                                         1.346 (1.318--1.374)                                         1.343 (1.315--1.371)
  ABSI                                                   1.136 (1.114--1.158)                                         1.066 (1.044--1.088)                                         1.064 (1.042--1.087)
  CVDs                                                                                                                                                                             
  BMI                                                    1.215 (1.178--1.253)                                         1.185 (1.148--1.225)                                         1.182 (1.143--1.221)
  WC                                                     1.412 (1.360--1.467)                                         1.315 (1.265--1.367)                                         1.307 (1.256--1.359)
  HC                                                     1.369 (1.317--1.422)                                         1.323 (1.271--1.377)                                         1.313 (1.261--1.367)
  WHR                                                    1.204 (1.164--1.245)                                         1.179 (1.137--1.223)                                         1.176 (1.134--1.220)
  WHtR                                                   1.495 (1.441--1.552)                                         1.362 (1.308--1.418)                                         1.353 (1.299--1.409)
  ABSI                                                   1.329 (1.280--1.380)                                         1.182 (1.135--1.230)                                         1.176 (1.130--1.224)

ABSI indicates A Body Shape Index; BMI, body mass index; HC, hip circumference; OR, odds ratio; WC, waist circumference; WHR, waist‐to‐hip ratio; WHtR, waist‐to‐height ratio.

Model 1: crude model.

Model 2: adjusted for sociodemographic characteristics (age, sex, regions, location, and education levels).

Model 3: adjusted for sociodemographic (age, sex, regions, location, and education levels), lifestyle (physical activity and daily energy intake), and medical history characteristics (family history of coronary heart disease or heart failure or other cardiovascular diseases \[CVDs\]).

Dyslipidemia: total cholesterol ≥5.2 mmol/L or low‐density lipoprotein cholesterol ≥3.4 mmol/L or high‐density lipoprotein cholesterol ≤1.0 mmol/L or triglycerides ≥1.7 mmol/L.

Abnormal blood pressure (BP): self‐reported hypertension or systolic BP ≥120 mm Hg and/or diastolic BP ≥80 mm Hg.

Hyperglycemia: self‐reported diabetes or fasting blood glucose level ≥5.6 mmol/L.

Table [3](#jah34181-tbl-0003){ref-type="table"} presents the AUCs (95% CIs) and optimal cut points for anthropometric measurements in relation to cardiometabolic risk factors and CVDs. The discriminatory ability of the anthropometric indices in identifying cardiometabolic risk factors and CVDs was not high. Compared with other cardiometabolic parameters, WHtR tended to be the best predictor for dyslipidemia (AUCs: 0.646, sensitivity 65%, specificity 44%, cutoff point: 0.49), hyperglycemia (AUCs: 0.595, sensitivity 60%, specificity 45%, cutoff point: 0.50), and CVDs (AUCs: 0.619, sensitivity 59%, specificity 41%, cutoff point: 0.52). WC showed the best prediction for abnormal BP (AUCs: 0.671, sensitivity: 66%, specificity: 40%, cutoff point: 78.20 cm). In this study, because of its higher specificity (from 39% to 57%) than other indices, the ABSI did not show better prediction (AUCs: from 0.540 to 0.597, cutoff point: from 0.75 to 0.77 m^7/6^/kg^2/3^), even if its sensitivity was similar to that of the other indices (from 53% to 64%).

###### 

AUCs and Optimal Cut Points for Anthropometric Measurements in Relation to Cardiometabolic Risk Factors and CVDs (N=44 048)

  Outcomes                                               AUC (95% CI)[a](#jah34181-note-0020){ref-type="fn"}   Cutoff Point   Sensitivity   Specificity   Youden Index
  ------------------------------------------------------ ----------------------------------------------------- -------------- ------------- ------------- --------------
  Dyslipidemia[b](#jah34181-note-0021){ref-type="fn"}                                                                                                     
  BMI                                                    0.627 (0.622--0.633)                                  23.55          0.68          0.49          0.19
  WC                                                     0.642 (0.636--0.647)                                  79.50          0.65          0.44          0.21
  HC                                                     0.607 (0.602--0.612)                                  94.35          0.56          0.41          0.16
  WHR                                                    0.618 (0.612--0.623)                                  0.85           0.62          0.45          0.18
  WHtR                                                   0.646 (0.641--0.651)                                  0.49           0.65          0.44          0.22
  ABSI                                                   0.589 (0.583--0.594)                                  0.75           0.63          0.49          0.14
  Abnormal BP[c](#jah34181-note-0022){ref-type="fn"}                                                                                                      
  BMI                                                    0.653 (0.647--0.659)                                  23.58          0.64          0.41          0.23
  WC                                                     0.671 (0.665--0.677)                                  78.20          0.66          0.40          0.26
  HC                                                     0.624 (0.618--0.629)                                  94.60          0.52          0.33          0.19
  WHR                                                    0.649 (0.643--0.656)                                  0.84           0.67          0.44          0.23
  WHtR                                                   0.664 (0.658--0.669)                                  0.50           0.60          0.36          0.24
  ABSI                                                   0.597 (0.591--0.603)                                  0.75           0.59          0.44          0.15
  Hyperglycemia[d](#jah34181-note-0023){ref-type="fn"}                                                                                                    
  BMI                                                    0.591 (0.586--0.596)                                  23.87          0.64          0.50          0.14
  WC                                                     0.588 (0.582--0.593)                                  80.40          0.60          0.46          0.13
  HC                                                     0.555 (0.549--0.560)                                  92.05          0.66          0.58          0.08
  WHR                                                    0.582 (0.577--0.588)                                  0.90           0.35          0.22          0.12
  WHtR                                                   0.595 (0.590--0.600)                                  0.50           0.60          0.45          0.15
  ABSI                                                   0.540 (0.535--0.546)                                  0.75           0.64          0.57          0.07
  CVDs                                                                                                                                                    
  BMI                                                    0.576 (0.565--0.587)                                  25.56          0.47          0.36          0.11
  WC                                                     0.601 (0.590--0.612)                                  82.50          0.59          0.43          0.15
  HC                                                     0.590 (0.579--0.602)                                  95.05          0.58          0.44          0.13
  WHR                                                    0.570 (0.559--0.581)                                  0.87           0.57          0.47          0.10
  WHtR                                                   0.619 (0.608--0.630)                                  0.52           0.59          0.41          0.18
  ABSI                                                   0.591 (0.580--0.602)                                  0.77           0.53          0.39          0.14

ABSI indicates A Body Shape Index; AUC, area under the receiver operating characteristic curve; BMI, body mass index; CVDs, coronary heart disease or heart failure or other cardiovascular diseases (arrhythmia, valvular heart disease, cardiomyopathy, and myocarditis); HC, hip circumference; WC, waist circumference; WHR, waist‐to‐hip ratio; WHtR, waist‐to‐height ratio.

Models adjusted for sociodemographic (age, sex, regions, location, and education levels), lifestyle (physical activity and daily energy intake), and medical history characteristics (family history of coronary heart disease or heart failure or other CVDs).

Dyslipidemia: total cholesterol ≥5.2 mmol/L or low‐density lipoprotein cholesterol ≥3.4 mmol/L or high‐density lipoprotein cholesterol ≤1.0 mmol/L or triglycerides ≥1.7 mmol/L.

Abnormal blood pressure (BP): self‐reported hypertension or systolic BP ≥120 mm Hg and/or diastolic BP ≥80 mm Hg.

Hyperglycemia: self‐reported diabetes or fasting blood glucose level ≥5.6 mmol/L.

Table [4](#jah34181-tbl-0004){ref-type="table"} compares the standardized ORs for each anthropometric measurement stratified by sex and age groups. For each index, the standardized OR for men was higher than for women. WHtR still showed a higher standardized OR than that of BMI, WC, HC, WHR, and ABSI for each cardiometabolic risk factor and CVDs for both men and women. For each anthropometric index, the ORs for middle‐aged people were higher than for the elderly except for HC in the association with abnormal BP. WHtR showed the highest OR for each cardiometabolic risk factor and CVDs in both middle‐aged and elderly people.

###### 

Adjusted ORs (Per 1‐SD Increase) for Cardiometabolic Risk Factors in Relation to Anthropometric Measurements, Stratified by Sex and Age Groups (N=44 048)

  Outcomes                                               Sex[a](#jah34181-note-0025){ref-type="fn"}   Age Groups[a](#jah34181-note-0025){ref-type="fn"}                          
  ------------------------------------------------------ -------------------------------------------- --------------------------------------------------- ---------------------- ----------------------
  Dyslipidemia[b](#jah34181-note-0026){ref-type="fn"}                                                                                                                            
  BMI                                                    1.723 (1.659--1.790)                         1.374 (1.335--1.413)                                1.558 (1.522--1.596)   1.321 (1.232--1.416)
  WC                                                     1.836 (1.771--1.903)                         1.480 (1.441--1.521)                                1.714 (1.675--1.753)   1.411 (1.323--1.505)
  HC                                                     1.593 (1.539--1.650)                         1.307 (1.273--1.343)                                1.453 (1.421--1.486)   1.348 (1.261--1.441)
  WHR                                                    1.690 (1.626--1.756)                         1.392 (1.351--1.433)                                1.603 (1.564--1.642)   1.335 (1.245--1.432)
  WHtR                                                   1.839 (1.775--1.904)                         1.504 (1.462--1.548)                                1.729 (1.690--1.770)   1.451 (1.358--1.552)
  ABSI                                                   1.361 (1.314--1.410)                         1.192 (1.160--1.224)                                1.338 (1.309--1.369)   1.176 (1.106--1.250)
  Abnormal BP[c](#jah34181-note-0027){ref-type="fn"}                                                                                                                             
  BMI                                                    1.837 (1.756--1.923)                         1.635 (1.582--1.690)                                1.829 (1.781--1.879)   1.819 (1.628--2.033)
  WC                                                     1.863 (1.782--1.947)                         1.721 (1.662--1.782)                                1.870 (1.819--1.922)   1.805 (1.611--2.022)
  HC                                                     1.617 (1.549--1.688)                         1.477 (1.430--1.525)                                1.560 (1.520--1.601)   1.689 (1.508--1.892)
  WHR                                                    1.621 (1.547--1.699)                         1.463 (1.413--1.515)                                1.630 (1.585--1.676)   1.480 (1.319--1.661)
  WHtR                                                   2.047 (1.945--2.154)                         1.758 (1.695--1.823)                                2.296 (2.010--2.622)   1.892 (1.836--1.949)
  ABSI                                                   1.179 (1.131--1.230)                         1.101 (1.068--1.134)                                1.235 (1.205--1.265)   1.014 (0.919--1.118)
  Hyperglycemia[d](#jah34181-note-0028){ref-type="fn"}                                                                                                                           
  BMI                                                    1.382 (1.336--1.430)                         1.253 (1.220--1.287)                                1.336 (1.306--1.366)   1.206 (1.136--1.281)
  WC                                                     1.350 (1.306--1.395)                         1.287 (1.253--1.322)                                1.388 (1.358--1.420)   1.194 (1.122--1.271)
  HC                                                     1.255 (1.213--1.297)                         1.161 (1.131--1.193)                                1.235 (1.208--1.262)   1.107 (1.040--1.178)
  WHR                                                    1.265 (1.222--1.310)                         1.248 (1.213--1.284)                                1.328 (1.298--1.360)   1.201 (1.125--1.283)
  WHtR                                                   1.399 (1.350--1.450)                         1.288 (1.253--1.325)                                1.419 (1.388--1.450)   1.247 (1.168--1.331)
  ABSI                                                   1.050 (1.015--1.087)                         1.045 (1.018--1.073)                                1.137 (1.112--1.163)   0.978 (0.923--1.035)
  CVDs                                                                                                                                                                           
  BMI                                                    1.237 (1.164--1.315)                         1.150 (1.105--1.196)                                1.206 (1.115--1.305)   1.189 (1.148--1.232)
  WC                                                     1.416 (1.317--1.523)                         1.247 (1.189--1.308)                                1.436 (1.375--1.500)   1.224 (1.124--1.332)
  HC                                                     1.371 (1.275--1.474)                         1.274 (1.213--1.338)                                1.342 (1.283--1.404)   1.264 (1.157--1.382)
  WHR                                                    1.246 (1.171--1.326)                         1.128 (1.077--1.182)                                1.239 (1.193--1.288)   1.107 (1.008--1.214)
  WHtR                                                   1.441 (1.343--1.546)                         1.292 (1.229--1.359)                                1.451 (1.387--1.517)   1.297 (1.187--1.417)
  ABSI                                                   1.254 (1.166--1.349)                         1.131 (1.077--1.187)                                1.330 (1.271--1.391)   1.055 (0.971--1.147)

ABSI indicates A Body Shape Index; BMI, body mass index; HC, hip circumference; OR, odds ratio; WC, waist circumference; WHR, waist‐to‐hip ratio; WHtR, waist‐to‐height ratio.

Models adjusted for sociodemographic (age, sex, regions, location, and education levels), lifestyle (physical activity and daily energy intake), and medical history characteristics (family history of coronary heart disease or heart failure or other cardiovascular diseases \[CVDs\]).

Dyslipidemia: total cholesterol ≥5.2 mmol/L or low‐density lipoprotein cholesterol ≥3.4 mmol/L or high‐density lipoprotein cholesterol ≤1.0 mmol/L or triglycerides ≥1.7 mmol/L.

Abnormal blood pressure (BP): self‐reported hypertension or systolic BP ≥120 mm Hg and/or diastolic BP ≥80 mm Hg.

Hyperglycemia: self‐reported diabetes or fasting blood glucose level ≥5.6 mmol/L.

AUCs for men and women and cutoff points for each parameter are demonstrated in Table [5](#jah34181-tbl-0005){ref-type="table"}. For men, WHtR is likely the best predictor for dyslipidemia (AUCs: 0.636, sensitivity: 70%, specificity: 45%, cutoff point: 0.49) and CVDs (AUCs: 0.622, sensitivity: 58%, specificity: 39%, cutoff point: 0.52) and BMI for abnormal BP (AUCs: 0.656, sensitivity: 61%, specificity: 38%, cutoff point: 23.71 kg/m^2^) and hyperglycemia (AUCs: 0.595, sensitivity: 59%, specificity: 44%, cutoff point: 24.28 kg/m^2^). However, in women, WC was superior for dyslipidemia (AUCs: 0.669, sensitivity: 63%, specificity: 43%, cutoff point:78.0 cm) and WHtR for abnormal BP (AUCs: 0.674, sensitivity: 62%, specificity: 36%, cutoff point: 0.50), hyperglycemia (AUCs: 0.601, sensitivity: 61%, specificity: 46%, cutoff point: 0.50), and CVDs (AUCs: 0.614, sensitivity: 56%, specificity: 38%, cutoff point: 0.52).

###### 

AUCs and Optimal Cut Points for Anthropometric Measurements in Relation to Cardiometabolic Risk Factors and CVDs, Stratified by Sex

  Outcomes                                               Men (n=18 139)         Women (n=25 909)                                                                      
  ------------------------------------------------------ ---------------------- ------------------ ------ ------ ------ ----------------------- ------- ------ ------ ------
  Dyslipidemia[b](#jah34181-note-0031){ref-type="fn"}                                                                                                                 
  BMI                                                    0.607 (0.600--0.614)   23.51              0.71   0.47   0.24   0.657 (0.649--0.665)    23.87   0.63   0.47   0.16
  WC                                                     0.628 (0.622--0.635)   82.45              0.68   0.43   0.25   0.669 (0.661--0.677)    78.0    0.63   0.43   0.20
  HC                                                     0.585 (0.579--0.592)   94.15              0.61   0.41   0.20   0.638 (0.630--0.646)    94.3    0.54   0.41   0.13
  WHR                                                    0.614 (0.607--0.621)   0.87               0.71   0.49   0.22   0.643 (0.63 5--0.651)   0.84    0.59   0.42   0.17
  WHtR                                                   0.636 (0.629--0.642)   0.49               0.70   0.45   0.25   0.662 (0.654--0.670)    0.51    0.54   0.34   0.20
  ABSI                                                   0.590 (0.583--0.597)   0.76               0.70   0.55   0.14   0.592 (0.583--0.600)    0.74    0.63   0.50   0.14
  Abnormal BP[c](#jah34181-note-0032){ref-type="fn"}                                                                                                                  
  BMI                                                    0.656 (0.646--0.666)   23.71              0.61   0.38   0.24   0.655 (0.648--0.663)    23.64   0.64   0.41   0.23
  WC                                                     0.653 (0.643--0.663)   81.95              0.63   0.39   0.23   0.668 (0.661--0.675)    77.85   0.61   0.35   0.26
  HC                                                     0.630 (0.620--0.640)   93.15              0.61   0.42   0.19   0.619 (0.612--0.626)    94.60   0.51   0.33   0.18
  WHR                                                    0.623 (0.613--0.634)   0.88               0.63   0.43   0.20   0.646 (0.638--0.653)    0.83    0.62   0.40   0.23
  WHtR                                                   0.654 (0.644--0.664)   0.48               0.70   0.47   0.23   0.674 (0.667--0.681)    0.50    0.62   0.36   0.26
  ABSI                                                   0.570 (0.560--0.580)   0.76               0.65   0.54   0.11   0.595 (0.587--0.603)    0.75    0.54   0.39   0.15
  Hyperglycemia[d](#jah34181-note-0033){ref-type="fn"}                                                                                                                
  BMI                                                    0.595 (0.587--0.604)   24.28              0.59   0.44   0.15   0.589 (0.582--0.596)    23.87   0.64   0.50   0.14
  WC                                                     0.581 (0.573--0.590)   83.05              0.61   0.49   0.12   0.590 (0.583--0.597)    79.05   0.57   0.44   0.14
  HC                                                     0.557 (0.549--0.566)   92.05              0.68   0.59   0.09   0.552 (0.545--0.559)    91.25   0.69   0.62   0.07
  WHR                                                    0.579 (0.570--0.587)   0.90               0.47   0.32   0.14   0.585 (0.578--0.592)    0.87    0.40   0.27   0.13
  WHtR                                                   0.590 (0.581--0.598)   0.50               0.58   0.44   0.14   0.601 (0.593--0.608)    0.50    0.61   0.46   0.15
  ABSI                                                   0.522 (0.514--0.531)   0.76               0.63   0.58   0.04   0.548 (0.541--0.555)    0.75    0.57   0.49   0.08
  CVDs                                                                                                                                                                
  BMI                                                    0.586 (0.568--0.604)   25.92              0.44   0.31   0.13   0.569 (0.555--0.584)    25.57   0.47   0.36   0.11
  WC                                                     0.620 (0.602--0.638)   88.05              0.51   0.33   0.18   0.608 (0.594--0.621)    82.25   0.52   0.36   0.16
  HC                                                     0.604 (0.586--0.622)   95.05              0.61   0.46   0.15   0.584 (0.571--0.598)    95.15   0.55   0.42   0.13
  WHR                                                    0.595 (0.590--0.600)   0.90               0.58   0.44   0.14   0.586 (0.572--0.600)    0.85    0.53   0.40   0.13
  WHtR                                                   0.622 (0.604--0.640)   0.52               0.58   0.39   0.19   0.614 (0.601--0.628)    0.52    0.56   0.38   0.18
  ABSI                                                   0.603 (0.585--0.622)   0.78               0.59   0.43   0.16   0.600 (0.587--0.614)    0.76    0.54   0.38   0.16

ABSI indicates A Body Shape Index; AUC, area under the receiver operating characteristic curve; BMI, body mass index; CVDs, coronary heart disease or heart failure or other cardiovascular diseases (arrhythmia, valvular heart disease, cardiomyopathy, and myocarditis); HC, hip circumference; WC, waist circumference; WHR, waist‐to‐hip ratio; WHtR, waist‐to‐height ratio.

Models adjusted for sociodemographic (age, sex, regions, location, and education levels), lifestyle (physical activity and daily energy intake), and medical history characteristics (family history of coronary heart disease or heart failure or other CVDs).

Dyslipidemia: total cholesterol ≥5.2 mmol/L or low‐density lipoprotein cholesterol ≥3.4 mmol/L or high‐density lipoprotein cholesterol ≤1.0 mmol/L or triglycerides ≥1.7 mmol/L.

Abnormal blood pressure (BP): self‐reported hypertension or systolic BP ≥120 mm Hg and/or diastolic BP ≥80 mm Hg.

Hyperglycemia: self‐reported diabetes or fasting blood glucose level ≥5.6 mmol/L.

Table [6](#jah34181-tbl-0006){ref-type="table"} shows the predictive values for each parameter stratified by age group. WHtR had the highest predictive value in middle‐aged people for dyslipidemia (AUCs: 0.647, sensitivity 64%, specificity 43%, cutoff point: 0.49), hyperglycemia (AUCs: 0.594, sensitivity 58%, specificity 44%, cutoff point: 0.50), and CVDs (AUCs: 0.614, sensitivity 57%, specificity 39%, cutoff point: 0.52). As for the elderly, BMI was superior for abnormal BP (AUCs: 0.696, sensitivity 64%, specificity 41%, cutoff point: 23.60 kg/m^2^) and hyperglycemia (AUCs: 0.584, sensitivity 70%, specificity 56%, cutoff point: 23.22 kg/m^2^).

###### 

AUCs and Optimal Cut Points for Anthropometric Measurements in Relation to Cardiometabolic Risk Factors and CVDs, Stratified by Age Groups

  Outcomes                                               35≤ Age \<65 y (n=39 632)   Age ≥65 y (n=4416)                                                                     
  ------------------------------------------------------ --------------------------- -------------------- ------ ------ ------ ---------------------- ------- ------ ------ ------
  Dyslipidemia[b](#jah34181-note-0036){ref-type="fn"}                                                                                                                       
  BMI                                                    0.630 (0.624--0.635)        24.34                0.59   0.40   0.20   0.609 (0.592--0.626)   23.43   0.68   0.50   0.17
  WC                                                     0.646 (0.640--0.651)        79.50                0.65   0.43   0.22   0.590 (0.573--0.607)   77.70   0.76   0.61   0.15
  HC                                                     0.609 (0.603--0.614)        94.10                0.58   0.42   0.16   0.588 (0.571--0.605)   96.65   0.45   0.32   0.13
  WHR                                                    0.622 (0.617--0.628)        0.85                 0.62   0.43   0.18   0.553 (0.537--0.571)   0.86    0.66   0.57   0.08
  WHtR                                                   0.647 (0.642--0.653)        0.49                 0.64   0.43   0.22   0.617 (0.600--0.634)   0.51    0.68   0.50   0.18
  ABSI                                                   0.591 (0.585--0.596)        0.74                 0.68   0.54   0.14   0.543 (0.525--0.560)   0.75    0.77   0.70   0.07
  Abnormal BP[c](#jah34181-note-0037){ref-type="fn"}                                                                                                                        
  BMI                                                    0.653 (0.647--0.659)        23.60                0.64   0.41   0.23   0.696 (0.670--0.721)   23.60   0.64   0.41   0.23
  WC                                                     0.668 (0.662--0.674)        78.20                0.65   0.40   0.25   0.665 (0.638--0.693)   77.70   0.72   0.46   0.26
  HC                                                     0.622 (0.616--0.628)        94.20                0.54   0.36   0.19   0.654 (0.627--0.680)   93.0    0.62   0.39   0.23
  WHR                                                    0.647 (0.641--0.653)        0.84                 0.66   0.43   0.23   0.608 (0.578--0.638)   0.83    0.78   0.57   0.21
  WHtR                                                   0.658 (0.652--0.664)        0.49                 0.62   0.38   0.23   0.674 (0.647--0.702)   0.49    0.72   0.44   0.28
  ABSI                                                   0.590 (0.583--0.596)        0.75                 0.61   0.47   0.14   0.546 (0.516--0.576)   0.78    0.52   0.42   0.10
  Hyperglycemia[d](#jah34181-note-0038){ref-type="fn"}                                                                                                                      
  BMI                                                    0.592 (0.587--0.598)        23.87                0.64   0.50   0.14   0.584 (0.567--0.601)   23.22   0.70   0.56   0.15
  WC                                                     0.589 (0.583--0.595)        80.80                0.57   0.44   0.13   0.549 (0.532--0.566)   80.10   0.67   0.58   0.09
  HC                                                     0.556 (0.550--0.562)        92.05                0.66   0.58   0.08   0.532 (0.515--0.549)   90.05   0.76   0.70   0.07
  WHR                                                    0.583 (0.577--0.589)        0.90                 0.34   0.21   0.12   0.545 (0.528--0.562)   0.87    0.60   0.52   0.08
  WHtR                                                   0.594 (0.589--0.600)        0.50                 0.58   0.44   0.15   0.561 (0.544--0.578)   0.50    0.67   0.57   0.10
  ABSI                                                   0.539 (0.533--0.545)        0.75                 0.62   0.56   0.07   0.515 (0.498--0.532)   0.76    0.63   0.56   0.07
  CVDs                                                                                                                                                                      
  BMI                                                    0.574 (0.561--0.587)        25.65                0.46   0.35   0.12   0.585 (0.562--0.609)   23.08   0.76   0.63   0.14
  WC                                                     0.597 (0.584--0.610)        82.05                0.59   0.44   0.15   0.578 (0.554--0.602)   85.60   0.52   0.34   0.13
  HC                                                     0.585 (0.572--0.597)        95.05                0.57   0.44   0.12   0.600 (0.576--0.623)   95.10   0.61   0.46   0.16
  WHR                                                    0.571 (0.558--0.583)        0.88                 0.49   0.38   0.11   0.519 (0.494--0.543)   0.85    0.69   0.63   0.06
  WHtR                                                   0.614 (0.601--0.626)        0.52                 0.57   0.39   0.18   0.580 (0.557--0.604)   0.52    0.63   0.50   0.13
  ABSI                                                   0.587 (0.575--0.599)        0.77                 0.50   0.37   0.13   0.525 (0.500--0.549)   0.78    0.58   0.51   0.07

ABSI indicates A Body Shape Index; AUC, area under the receiver operating characteristic curve; BMI, body mass index; CVDs, coronary heart disease or heart failure or other cardiovascular diseases (arrhythmia, valvular heart disease, cardiomyopathy, and myocarditis); HC, hip circumference; WC, waist circumference; WHR, waist‐to‐hip ratio; WHtR, waist‐to‐height ratio.

Models adjusted for sociodemographic (age, sex, regions, location, and education levels), lifestyle (physical activity and daily energy intake), and medical history characteristics (family history of coronary heart disease or heart failure or other CVDs).

Dyslipidemia: total cholesterol ≥5.2 mmol/L or low‐density lipoprotein cholesterol ≥3.4 mmol/L or high‐density lipoprotein cholesterol ≤1.0 mmol/L or triglycerides ≥1.7 mmol/L.

Abnormal blood pressure (BP): self‐reported hypertension or systolic BP ≥120 mm Hg and/or diastolic BP ≥80 mm Hg.

Hyperglycemia: self‐reported diabetes or fasting blood glucose level ≥5.6 mmol/L.

Discussion {#jah34181-sec-0016}
==========

Using baseline data from a large prospective cohort study among Chinese participants, we found strong evidence for a positive association between obesity‐related anthropometric indices and cardiometabolic risk factors and CVDs, but these measures had only moderate discriminatory ability for predicting these cardiometabolic risk factors. The results of this study indicated that markers of central obesity measured by WHtR were more strongly related to dyslipidemia, hyperglycemia, and CVDs risk than BMI.

The strong associations shown in this study between obesity‐related indices and cardiometabolic risk factors and CVDs were consistent with previous studies from both the developed and developing countries.[11](#jah34181-bib-0011){ref-type="ref"}, [12](#jah34181-bib-0012){ref-type="ref"}, [13](#jah34181-bib-0013){ref-type="ref"}, [15](#jah34181-bib-0015){ref-type="ref"}, [37](#jah34181-bib-0037){ref-type="ref"}, [38](#jah34181-bib-0038){ref-type="ref"}, [39](#jah34181-bib-0039){ref-type="ref"} In this study, when calculating ORs that allow adjusting for further confounding factors, WHtR showed a slightly stronger association with all cardiometabolic risk factors and CVD risk than that of any other indices. Possibly, WHtR takes height into account, which is more sensitive to muscle mass distribution and has a better interpretation on the whole body shape. Men showed higher ORs than women in this study, which is similar to that found in previous studies[21](#jah34181-bib-0021){ref-type="ref"}, [40](#jah34181-bib-0040){ref-type="ref"} on the association between obesity‐related indices and cardiometabolic risk factors and CVDs. This could be partially explained by other modified risk factors (ie, smoking or drinking) and the diversity of fat and muscle distributions. We found that in middle‐aged people, anthropometric indices had stronger associations with cardiometabolic risk factors and CVDs. The gain of fat mass and loss of lean mass with increasing age may interpret the differences.[41](#jah34181-bib-0041){ref-type="ref"}, [42](#jah34181-bib-0042){ref-type="ref"}

Two previous reviews of meta‐analyses combining 30 and 31 studies indicated that WHtR was a better predictor for cardiometabolic risk factors and CVD risk than BMI and WC.[16](#jah34181-bib-0016){ref-type="ref"}, [17](#jah34181-bib-0017){ref-type="ref"} Our results also indicate that WHtR may be the best index to predict dyslipidemia, hyperglycemia, and CVD risk compared with all other anthropometric parameters. This may be explained by the fact that WHtR does not misclassify muscular but low body fat individuals as BMI does. However, we found WC was a slightly better predictor for abnormal BP. WC is regarded as a visceral fat indicator and reflects both lean and fat mass, which has been shown to be more closely related to high BP than BMI. ABSI as a new body shape index has been used to predict CVD mortality in 4 European populations with HRs (95% CIs) per SD increase of 1.34 (1.26--1.44).[20](#jah34181-bib-0020){ref-type="ref"} In this study, a positive association was also observed between ABSI and all cardiometabolic risk factors and CVDs both in univariate and multivariable models (*P*\<0.001). However, in this study, ABSI did show this superiority over any other traditional obesity‐related indices, which may be related to the distinct difference in body figures between Chinese and white people. Based on previous studies, the cutoff value of ≈0.5 for WHtR was considered properly for the Asian population.[40](#jah34181-bib-0040){ref-type="ref"}, [43](#jah34181-bib-0043){ref-type="ref"}, [44](#jah34181-bib-0044){ref-type="ref"} Our study suggests a similar cutoff value (range, 0.49--0.52).

Study Strengths {#jah34181-sec-0017}
---------------

The main strengths of the present study are the large size of the study population and standardized measures and high quality of data. We measured and compared detailed information of different anthropometric measurements of both the traditional and new‐built indices in the same population, which presented a whole picture of the predictive values of all anthropometric parameters in a single Chinese population.

Study Limitations {#jah34181-sec-0018}
-----------------

Several limitations of the present study should be considered. First, our study used only baseline data from the PURE‐China cohort, and cause and effect may not be inferred from this study alone. Our results only assessed the predictive abilities of anthropometric indices on prevalence and did not directly predict the prospective risk of cardiovascular events. Therefore, the results of the current study should be verified by further follow‐up studies. In addition, we recognize that misclassification of disease diagnoses is a concern, as they were self‐report and not further verified by medical record or available laboratory tests. This misclassification, however, was likely to be nondifferential, which led to an underestimation of reported associations.

Conclusions {#jah34181-sec-0019}
===========

This study suggests that there is a positive association of obesity‐related anthropometric indices with cardiometabolic risk factors and CVDs. WHtR appeared to be a better indicator of dyslipidemia, hyperglycemia, and CVD risk than BMI, WC, HC, WHR, and ABSI. A growing body of evidence supports that avoidance of abdominal obesity is the prioritized primary prevention strategy for CVDs, along with control of other major CVD risk factors.

Appendix {#jah34181-sec-0020}
========

PURE‐China Investigators (\*Regional PI, \*\*National PI) {#jah34181-sec-0021}
---------------------------------------------------------
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[^1]: A complete list of the PURE (Prospective Urban Rural Epidemiology) investigators can be found in the Appendix at the end of this article.
